Disse B G
Dr. Karl Thomae GmbH, Department of Biological Research, Biberach an der Riss, Fed. Rep. Germany.
Eur J Respir Dis Suppl. 1987;153:255-62.
The major pharmacodynamic actions of ambroxol are surfactant stimulation, mucokinetic and secretagogue activity. The therapeutic activities of the drug in animal models of the infant and adult respiratory distress syndrome (IRDS and ARDS) are reviewed. SO2 exposed rats, which exhibited increased airway resistance and work of breathing, were used as an animal model of a bronchitic syndrome. The active group was treated with 25 mg kg-1 oral ambroxol for 10 days. The airway resistance of this group (53.6 +/- 7.0 Pa.ml-1.s) was significantly lower than that of the control (81.2 +/- 11.4). Specific work of breathing was also lower in the treated group (0.26 +/- 0.02 mJ.ml-1, control: 0.35 +/- 0.029). The alleviation of airflow limitation was a consequence of subacute treatment and not of acute bronchodilatation. Treatment with the beta 2-adrenergic drug clenbuterol further improved both active and placebo groups.
氨溴索的主要药效学作用为刺激表面活性物质、促黏液运动及促分泌活性。本文综述了该药物在婴儿和成人呼吸窘迫综合征（IRDS和ARDS）动物模型中的治疗活性。将暴露于二氧化硫后出现气道阻力增加和呼吸功增加的大鼠作为支气管综合征的动物模型。活性组用25mg/kg口服氨溴索治疗10天。该组的气道阻力（53.6±7.0Pa·ml-1·s）显著低于对照组（81.2±11.4）。治疗组的比呼吸功也较低（0.26±0.02mJ·ml-1，对照组：0.35±0.029）。气流受限的缓解是亚急性治疗的结果，而非急性支气管扩张的结果。用β2-肾上腺素能药物克仑特罗治疗可使活性组和安慰剂组均进一步改善。
